
NEW ORLEANS--A test based on the newly developed monoclonal antibody NMP179 can detect both low-grade and high-grade cervical dysplasia, according to results presented at the 89th annual meeting of the American Association for Cancer Research. The developers believe the test might one day be used as a supplement to the Pap smear.
